<DOC>
	<DOCNO>NCT02556671</DOCNO>
	<brief_summary>Dual antiplatelet therapy ( DAPT ) standard dose aspirin clopidogrel long cornerstone patient undergo percutaneous coronary intervention ( PCI ) . However , inhibition platelet activation aggregation DAPT vary greatly among patient . Some clinical study demonstrate patient high on-treatment platelet reactivity increase risk major adverse cardiovascular event . Tailored antiplatelet therapy seem offer opportunity improve outcome coronary stenting drug adjustment base platelet function test . Unfortunately , result 3 major prospective trial ( GRAVITAS , ARCTIC , TRIGGER PCI ) personalize antiplatelet therapy neutral . In study , platelet function assess single measurement single method early start antiplatelet treatment . To test stability platelet reactivity measurement time among patient undergo PCI , investigator use 3 method ( VerifyNow P2Y12 assay , Flow cytometric assessment phosphorylation status VASP , light transmittance aggregometry ) platelet function test 2 period ( ~14days ) , maintenance dos clopidogrel .</brief_summary>
	<brief_title>Platelet Reactivity After Receiving Clopidogrel Among Moderate CKD Patients Undergoing PCI</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>1 . &gt; 18 year old . 2.15 â‰¤ eGFR &lt; 60 ml/min/1.73 m2 . 3 . Clinically stable follow PCI 4 week 1 year . 4 . On clopidogrel ( 75mg/d ) aspirin ( 100mg/d ) treatment least 4 week . 1 . Conditions alter platelet function . 2 . Conditions increase bleed risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>